Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Alliance Grants

McMaster University

$50,000.00

Intranasal delivery of neutralizing antibodies for prophylatic COVID-19 treatments_x000d_ _x000d_ _x000d_ _x000d_ _x000d_

EF 2020-21

Résumé
Technologies for passive immunity have the potential to decrease the transmission of SARS-CoV-2 in our communities and high-risk environments such as long term care homes. The intranasal delivery of virus neutralizing antibodies prior or soon after exposure to SARS-CoV-2 can prevent infection, which is a form of passive immunity. Therefore, intranasal delivery of neutralizing antibodies can prevent exposed individuals from getting sick and prevent the spread of disease. Passive immunity therapies are required as an alternative to vaccines, which may take multiple years to develop and fully implement. Furthermore, high risk populations such as the elderly have poor vaccine response rates, limiting their effectiveness. To this end, we are developing delivery technologies to sustain the delivery of neutralizing antibodies for SARS-CoV-2 that can be administered through a simple nasal spray. Our goal is to decrease virus transmission in the community, which will allow for a greater quality of life and potentially eliminate the need for lockdowns.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
555162-2020
Name nom
Wylie, Ryan
Department département
Chemistry & Chemical Biology
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
50000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Intranasal delivery of neutralizing antibodies for prophylatic COVID-19 treatments_x000d_ _x000d_ _x000d_ _x000d_ _x000d_
Keyword
NSERC
Application summary
Technologies for passive immunity have the potential to decrease the transmission of SARS-CoV-2 in our communities and high-risk environments such as long term care homes. The intranasal delivery of virus neutralizing antibodies prior or soon after exposure to SARS-CoV-2 can prevent infection, which is a form of passive immunity. Therefore, intranasal delivery of neutralizing antibodies can prevent exposed individuals from getting sick and prevent the spread of disease. Passive immunity therapies are required as an alternative to vaccines, which may take multiple years to develop and fully implement. Furthermore, high risk populations such as the elderly have poor vaccine response rates, limiting their effectiveness. To this end, we are developing delivery technologies to sustain the delivery of neutralizing antibodies for SARS-CoV-2 that can be administered through a simple nasal spray. Our goal is to decrease virus transmission in the community, which will allow for a greater quality of life and potentially eliminate the need for lockdowns.